Statistics for Sustained Complete Response to Palbociclib in a Refractory Pediatric Sarcoma With BCOR-CCNB3 Fusion and Germline CDKN2B Variant
Total visits
| views | |
|---|---|
| Sustained Complete Response to Palbociclib in a Refractory Pediatric Sarcoma With BCOR-CCNB3 Fusion and Germline CDKN2B Variant | 85 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| PO.19.00258.pdf | 241 |
| java.util.UUID:350a9ff0-25eb-42fc-978d-d7dbb47a0274 | 54 |
| java.util.UUID:9c44cb2f-24e4-4078-80a9-49691725c0ac | 3 |
| java.util.UUID:7d6cfa69-60bb-469e-bc13-4e205e3501c9 | 2 |
Top country views
| views | |
|---|---|
| United States | 68 |
| Canada | 2 |
| China | 1 |
| Germany | 1 |
| Malaysia | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 41 |
| Fairfield | 9 |
| Chicago | 4 |
| Cambridge | 2 |
| Houston | 2 |
| Toronto | 2 |
| Ann Arbor | 1 |
| Baltimore | 1 |
| Beijing | 1 |
| Indianapolis | 1 |
| Kiez | 1 |
| San Francisco | 1 |
| Seremban | 1 |
| Stockholm | 1 |
| White Plains | 1 |